云顶新耀医药科技有限公司 EVEREST MEDICINES
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Everest Medicines Announces Approval of Clinical Trial Application by China NMPA for Phase 3 Trial of Xerava(TM) for Community-Acquired Bacterial Pneumonia 2021-08-05 13:12
Everest Medicines Receives Pediatric and Rare Severe Disease Priority Review Designation from Taiwan FDA for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer 2021-07-29 18:41
Everest Medicines Announces Strategic Collaboration with MediTrust Health Co., Ltd to Develop Novel Payment Solutions for Patients in China 2021-07-20 18:42
Everest Medicines Announces Strategic Collaboration with Medbanks Health Technology to Develop Innovative Healthcare Service Solutions for Patients in China 2021-07-13 19:47
Everest Medicines Announces Strategic Commercial Partnership with Global Technology Company, Tencent 2021-07-12 12:42
Everest Medicines Announces that Spero Therapeutics Entered into Licensing Agreement with Pfizer Inc. for SPR206 in ex-U.S. and ex-Asia Territories 2021-07-05 18:16
Everest Medicines Announces China NMPA Has Granted Priority Review for Sacituzumab Govitecan-hziy in Metastatic Triple-Negative Breast Cancer 2021-05-20 19:04
Everest Medicines Announces China NMPA Has Accepted Biologics License Application for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer 2021-05-17 16:51
Everest Medicines Receives Orphan Drug Designation from the Ministry of Food and Drug Safety in South Korea for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer 2021-05-06 08:30
Everest Medicines Appoints Jennifer Yang as Chief Scientific Officer 2021-04-15 08:36
Everest Medicines Announces that the US FDA has Granted Licensing Partner Gilead Sciences, Inc. Accelerated Approval of Trodelvy® for the Treatment of Metastatic Urothelial Cancer 2021-04-14 21:33
Everest Medicines Announces that Licensing Partner Gilead Sciences, Inc. has Received Full US FDA Approval of Trodelvy® for the Treatment of Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer 2021-04-09 08:30
Everest Medicines Announces China NMPA Approval of Clinical Trial Application to Evaluate Trodelvy® in a Phase 2 Basket Trial for a Variety of Cancers with High TROP-2 Expression 2021-03-31 10:27
Everest Medicines Announces Financial Results for Full Year Ended December 31, 2020 2021-03-22 15:06
Everest Medicines Announces Acceptance of New Drug Application by China NMPA for Xerava(TM) for the Treatment of Complicated Intra-abdominal Infections 2021-03-22 10:40
Everest Medicines to Announce Full-Year 2020 Financial Results on March 22, 2021 2021-03-19 14:43
Everest Medicines Announces Selection as a Constituent of Certain Indexes of Hang Seng Indexes Company Limited 2021-03-01 12:36
Everest Medicines Appoints Kevin Guo as Chief Commercial Officer 2021-02-18 12:26
Everest Medicines Appoints Kevin Guo as Chief Commercial Officer 2021-02-18 12:21
Everest Medicines Announces Amended Agreement with Spero Therapeutics 2021-01-18 18:05
1 3 4 5 6 7